Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
173.78(c) 173.23(c) 175.45(c) 173.42(c) 170.06(c) Last
907 149 1 023 565 904 998 971 193 913 948 Volume
+0.91% -0.32% +1.28% -1.16% -1.94% Change
More quotes
Financials (USD)
Sales 2018 2 987 M
EBIT 2018 1 023 M
Net income 2018 733 M
Finance 2018 2 747 M
Yield 2018 -
Sales 2019 3 525 M
EBIT 2019 1 353 M
Net income 2019 805 M
Finance 2019 3 920 M
Yield 2019 -
P/E ratio 2018 60,12
P/E ratio 2019 57,66
EV / Sales2018 13,6x
EV / Sales2019 11,2x
Capitalization 43 460 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (87%); - income from... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
12/13VERTEX PHARMACEUTICALS : Health Canada Grants Market Authorization for ORKAMBI® ..
BU
12/11VERTEX PHARMACEUTICALS : U.K. government says Orkambi must go through proper NIC..
AQ
12/08Moderna Declines in Market Debut -- WSJ
DJ
12/07Moderna Declines in Public-Market Debut
DJ
12/07Moderna sets IPO record with upsized $604M offering
AQ
12/03VERTEX PHARMACEUTICALS : NICE, NHS miss Orkambi deadline
AQ
11/30VERTEX PHARMACEUTICALS : announces European Commission approval for KALYDECO
AQ
11/29Moderna proposes terms for record IPO
AQ
11/29VERTEX PHARMACEUTICALS : `s Triple-Combo CF Drugs Dazzle in Preliminary Data fro..
AQ
11/29VERTEX PHARMACEUTICALS : Announces European Commission Approval for KALYDECO® (i..
PU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 202 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian Frederick Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS15.72%43 460
GILEAD SCIENCES-8.47%84 823
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469